Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paracetamol versus paracetamol plus celecoxib or ibuprofen for paediatric burn injury
ACTRN12626001096347Phase 2Not yet recruiting
- Sponsor
- Griffith University
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in burn injury comparing Standard care paracetamol, Paracetamol plus celecoxib and Paracetamol plus ibuprofen (3 arms). Primary endpoint: Composite safety outcome associated with non-steroidal anti-inflammatory drug treatment. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
acetaminophencelecoxibibuprofen
03
Conditions
burn injury
Beyond the preview
Go deeper on ACTRN12626001096347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001096347.